The interactions between the individual domains (E, D, A, B and C) of staphylococcal protein A (SPA) and Fc and Fab regions of human immunoglobulins were studied using real-time biospecific interaction analysis. An engineered domain Z, similar to fragment B but with a single glycine to alanine amino acid substitution, was also included in the study. The domains were expressed in Escherichia coli, affinity purified and immobilised onto sensor chip surfaces in a directed manner using a unique C-terminal cysteine residue engineered into the recombinant proteins. All domains bound to a recombinant human IgG1 Fc fragment with similar strength. For the first time, binding to human Fab was demonstrated for all native SPA domains, using both polyclonal F(abP) P and a recombinant scFv fragment as reagents. Interestingly, the engineered Z domain showed a considerably lower affinity for Fab as compared to the native domains. z 1998 Federation of European Microbiological Societies. Published by Elsevier Science B.V.
Introduction
Staphylococcal protein A (SPA) is widely used as an immunological tool and as an a¤nity handle for production of recombinant proteins through its binding to immunoglobulins [1^4] . In fact, the interaction between SPA and immunoglobulins is one of the most studied protein-protein interactions. SPA contains ¢ve homologous domains showing strong a¤nity for the Fc region of human immunoglobulin G, the`classical' interaction of protein A [5] . However, SPA has also been shown to bind to certain Fab fragments in an`alternative' interaction [6, 7] . To date, there have been limited e¡orts to analyse the relative binding strengths of the ¢ve individual homologous SPA domains towards Fab and Fc, respectively. It has been indicated that not all domains are involved in the Fab interaction [8] . Recently, it was demonstrated that domain D binds to Fab, but the other individual domains were not included in the study [9] .
The present investigation was undertaken to individually investigate each of the ¢ve individual SPA domains for their interactions with human Fab. Domain Z, a widely used monovalent SPA analogue based on domain B [10] , was also included in the study. The domains were individually produced in Escherichia coli, £anked by a serum albumin binding a¤nity fusion partner and a unique cysteine residue, respectively, facilitating their puri¢cation by HSA a¤nity and immobilisation for binding analysis. The binding experiments were performed using surface plasmon resonance supported biospeci¢c interaction analysis (BIA), giving fast real-time measurements of binding [11] . In the study, interactions between individual SPA-derived domains and recombinant human Fc fragments, a single chain Fv fragment (scFv) and human polyclonal F(abP) P were analysed and compared.
Materials and methods

Recombinant DNA techniques
General recombinant DNA techniques were followed [12] except where indicated. Transformations were either performed as electroporations using a Gene Pulser (Bio-Rad) or to freeze-competent bacteria. Plasmid DNA was puri¢ed using QIA20 or QIA100 columns and corresponding bu¡ers from Diagen (Germany).
Isolation of SPA-encoding DNA fragments
The genes encoding the di¡erent Ig-binding domains of SPA were isolated using PCR as shown in Fig. 1 using the oligonucleotides described in Table 1. The templates were either puri¢ed plasmid DNA or E. coli cells (containing the indicated plasmids) from glycerol stocks frozen in 380³C, lysed by heating to 98³C for 5 min in the presence of 0.1% Tween prior to PCR.
The gene encoding domain E was isolated by PCR using E. coli containing pASEB [13] as template. Genes encoding domains D, A and B were isolated using E. coli containing pRIT2T (Pharmacia Biotech) as PCR template, the gene for domain C was ampli¢ed from a restriction fragment, HaeII-EcoRI from plasmid pRIT22 [10] and the gene encoding domain Z was ampli¢ed from E. coli cells containing pEZCYS [14] . The genes encoding domains D and A, respectively, were isolated using the same downstream oligonucleotide PCR primer, but di¡erent upstream primers. The resulting PCR product also contained a fragment encoding regions D and A, resulting from ampli¢cation by primers JABI77 and JABI85, but the fragments could easily be separated by gel electrophoresis. The genes encoding domains B and C, respectively, were isolated using the same primer pair. However, the template for domain B contained a truncated C domain gene, yielding only the gene for domain B when ampli¢ed using primers JABI81 and JABI86. The PCR ampli¢cations were run in thin-walled tubes using a GeneAmp 9600 instrument (PerkinElmer) under the following conditions: 94³C 5 min; 96³C 15 s, 55³C 20 s, 72³C 30 s, repeated 35 times; 72³C 10 min. The reaction mixtures contained 30 pmol of each primer in a standard bu¡er (PerkinElmer). Table 1 Oligonucleotides used for vector construction by PCR Name Sequence Length (nt)   LAMA17  5P-CCGAATTCGCTAGCTTAGCTGAAGCTAAAGTCTTAG-3P  36  LAMA18  5P-GCGGTACCAGGTAATGCAGCTAAAATTTCAT C-3P  32  JABI75  5P-GCGGTACCGCGCAACACGATGAAGCTCA-3P  28  JABI77  5P-GCGGTACCGCTGATAACAATTTCAACAA-3P  28  JABI79  5P-GCGGTACCGCTGATAACAATTTCAACAA-3P  28  JABI81  5P-GCGGTACCGCGGACAACAAATTCAACAA-3P  28  JABI83  5P-GCGGTACCGTAGACAACAAATTCAACAA-3P  28  JABI84  5P-GGGAAGCTTAGGATCCGCAGGATCCTTTTGGAGCTTGAGAGTCAT-3P  45  JABI85 5P
5P-GGGAAGCTTAGGATCCGCAGGATCCTTTCGGCGCCTGAGCATCAT-3P 45
Vector construction
The vectors for the expression of the SPA fragments fused to the albumin binding region of SPG were assembled in two steps. First, the plasmid pBJ100 was constructed and this vector was used to clone the di¡erent SPA domains. The plasmid pB2T [15] was used as template in a PCR ampli¢ca-tion with the primers LAMA17 and LAMA18 (Table 1). The PCR product obtained, encoding a monovalent serum albumin binding region of SPG, was puri¢ed using Millipore Ultrafree NMWL 30.000 ¢lters. The PCR product was digested with the restriction endonucleases NheI and KpnI and the resulting 160-bp fragment was ligated to the vector fragment from pT7-ABP [16] restricted with NheI and KpnI. The ligation mixture was transformed to E. coli RRIvM15 [17] by electroporation. Puri¢ed plasmid DNA from the resulting transformants was prepared and analysed using restriction enzymes to isolate a correct pBJ100 (Fig. 1) .
PCR fragments encoding the di¡erent SPA domains were subsequently inserted into the pBJ100 vector, using the KpnI and HindIII sites. After transformation to E. coli RRIvM15 [17] , plasmid DNA from the resulting transformants was prepared and analysed by restriction enzyme digestion prior to solid phase DNA sequencing of positive clones [18, 19] . The resulting expression vectors were denoted pBJ100E, pBJ100D, pBJ100A, pBJ100B, pBJ100C and pBJ100Z, respectively.
Expression and puri¢cation of fusion proteins
For protein expression E. coli BL21(DE3)pLysS cells were used (Novagen). Shake £asks with tryptic soy broth (TSB) supplemented with ampicillin (150 mg l 3I ) and chloramphenicol (34 mg l 3I ) were inoculated with cells from frozen glycerol stocks and grown for 2^3 h before overnight storage in 4³C. For production, shake £asks containing 25^100 ml of medium were inoculated with 1/50 volume of cultures stored overnight and grown at either 30³C or 37³C until an OD THHnm between 0.5 and 1.5 was reached. The production of fusion protein was induced with the addition of IPTG to 1 mM ¢nal concentration and allowed to continue for 2^5 h after which the cells were pelleted. Cells were resuspended in 1UTST bu¡er (25 mM Tris, 200 mM NaCl, 0.05% (w/v) Tween 20), with 1/5 of the original volume and subsequently frozen to facilitate lysis. The thawed cell suspension was sonicated using a VibraCell soni¢er (Sonics and Materials, Inc.) micro tip for 5 min (pulsed mode, level 5, 70% duty cycle). The sonicated suspension was centrifuged at 30 000Ug for 10 min. The supernatant was loaded on an HSA-Sepharose 4B a¤nity column (1.5^2 ml gel) [20] . After binding, the column was washed with 15^20 column volumes 1UTST, and equilibrated with 5 mM ammonium acetate (pH 5) before elution of bound fusion protein with 0.5 M acetic acid pH 2.8. The puri¢ed fusion protein fractions were lyophilised and analysed by SDS-PAGE using the Phast System (Pharmacia Biotech). The yields of fusion protein, calculated after lysis and HSA-a¤nity puri¢cation, corresponded to between 6 and 30 mg per litre culture medium. SDS-PAGE analysis of puri¢ed, lyophilised fusion protein under non-reducing conditions suggested that approximately 50% of the material formed dimers under these conditions (data not shown). 
Expression and puri¢cation of antibody fragments
An anti-human p53 protein single chain Fv fragment (clone no. 30) [21] was expressed from a plasmid construct based on the pHEN1 vector [22] . The expressed scFv construct contains the V r 3 chain of germline DP-53 [21, 23] linked to a V v chain via a (GGGGS) Q spacer and is followed by a C-terminal cmyc tag sequence [21, 22] . The scFv construct, which is secreted using the PelB signal peptide, was expressed in E. coli HB2151 [24] as described earlier [22] . Brie£y, 400 ml 2UYT with 0.1% glucose and ampicillin (100 mg l 3I ) was inoculated from a frozen glycerol stock and shaken at 30³C until an OD THHnm of 0.6 was reached and the bacteria were pelleted by centrifugation. The pellet was resuspended in 350 ml fresh 2UYT containing ampicillin (100 mg l 3I ) and IPTG (0.8 mM). The ba¥ed £ask was shaken at 30³C for 13 h after which the cells were removed by centrifugation and the clear medium was ¢ltered through a 0.45 Wm ¢lter. The ¢ltrate was puri¢ed on a protein AG-Sepharose column. The a¤nity column was washed with 20 column volumes 1UTST and equilibrated with 5 mM ammonium acetate (pH 5) before elution with 0.5 M acetic acid pH 2.8. The eluted fractions were lyophilised and the purity was controlled by SDS-PAGE. The yield of scFv fragment after puri¢cation was approximately 2.6 mg per litre culture medium. The protein AG-Sepharose column was made from CNBr-activated Sepharose 4B (Pharmacia Biotech) according to the protocol from the manufacturer. The recombinant protein AG is a fusion between immunoglobulin-binding domains from SPA and SPG previously described [25] .
The constant regions from human IgG1 and 3 (Fc1* and Fc3) were expressed in the E. coli strain KS476 [26] from the plasmids pEFc1* and pEFc3, respectively, derivatives of pEZZ18 [27] with the ZZ encoding fragment replaced by fragments encoding the Fc1* or Fc3 proteins. Fc1* is functionally equivalent to Fc1 in terms of SPA binding but contains the hinge and framework of Fc3. The two amino acid residues crucial for the lack of SPA binding in Fc3 have been mutated to the corresponding residues from Fc1 (R466H, F467Y) yielding Fc1* (numbering according to [28] ). The SPA binding of Fc1* has earlier been utilised in binding analyses [29] , but a more detailed description of the construction and characterisation of Fc1* is presented elsewhere [30] .
E. coli KS476 cells containing the plasmids pEFc1* and pEFc3, respectively, were inoculated from agar plates into 500 ml TSB supplemented with yeast extract (5 g l 3I ) and ampicillin (200 mg l 3I ). The £asks were shaken at 30³C for 40^45 h and the cells were subsequently pelleted by centrifugation and subjected to osmotic shock. Brie£y, the pellet was resuspended in a ¢fth of the original volume of sucrose solution (20% (w/v) sucrose, 0.3 M TrisHCl pH 8.0, 1 mM EDTA) and kept on ice for 20 min, pelleted by centrifugation after which an equal volume of water was added. After 5 min incubation at 0³C, the solution was centrifuged at 16 000Ug for 15 min. The supernatant was ¢ltered through a 0.45 Wm ¢lter before it was run through a protein G-Sepharose 4 FF column (Pharmacia Biotech). After binding of the sample, the column was washed with 20 volumes 1UTST, equilibrated with 5 mM ammonium acetate (pH 6.0). Elution was performed with 0.5 M acetic acid pH 2.8, and the peak fractions subsequently lyophilised. The yields after puri¢cation corresponded to around 8 mg per litre culture for each Fc fragment. Lyophilised protein pools were subsequently resuspended in 6 M guanidinium hydrochloride/HBS or 6 M GuHCl/50 mM ammonium acetate and dialysed against HBS or 50 mM ammonium acetate, respectively, using Spectra/Por membranes with a molecular mass cut-o¡ of 6^8 kDa.
Binding experiments using BIAcore
The binding experiments were performed using a BIAcore instrument (Pharmacia Biosensor). The fusion proteins between the albumin binding domain of SPG and the di¡erent SPA domains were used as ligands, i.e. immobilised onto the biosensor chip. The immobilisations were performed according to the suppliers recommendations, employing the free thiol group of the cysteine in the C-termini of the fusion proteins. Brie£y, 2-(2-pyridinyldithio) ethaneamine hydrochloride (PDEA) was injected over an activated CM-5 sensor chip matrix to give reactive disul¢de groups prior to the addition of the ligand. Prior to immobilisation, the ligands were reduced in 10 mM dithiothreitol (DTT) followed by desalting on G-25 Sephadex (NAP-5, Pharmacia Biotech) into 50 mM ammonium acetate pH 4.0. The fusion proteins were immobilised on the chip surfaces to levels in the range of 900^1300 RU (response units). Immobilised fusion proteins were tested for binding to recombinant antibody fragments as described above: Fc1*, Fc3 and a scFv (anti-p53; human V r 3). In addition, also the binding to polyclonal human F(abP) P (Jackson ImmunoResearch, USA) and human serum albumin (Sigma A-8763) was investigated. The running bu¡er in the experiments was HBS (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.05% BIAcore surfactant P20) and regeneration of the surfaces between runs was performed with 50 mM HCl. For evaluation of binding kinetics, di¡erent concentrations of anti-p53 scFv (100^2000 nM) were passed over each immobilised ligand. Kinetic parameters were determined using BIAevaluation 2.1 software (Pharmacia Biosensor).
Protein concentration determination
Preliminary measurements of protein concentrations were made spectrophotometrically at 280 nm. Exact measurements of analyte concentrations for BIAcore experiments were performed by amino acid analysis using a Beckman 6300 Amino Acid Analyzer. The hydrolysis was performed in 6 M HCl at 155³C for 45 min after which the sample was analysed on an ion-exchange column and the individual amino acids detected by ninhydrin.
Results
Design, expression and puri¢cation of proteins
The genes encoding the E, D, A, B and C domains of SPA and the domain B analogue Z were separately isolated by PCR from plasmid templates using oligonucleotide primers introducing endonuclease restriction sites for further cloning (Fig. 1) . Individual domains were produced in E. coli as C-terminal fusions to a 5 kDa serum albumin binding domain (ABD) derived from streptococcal protein G [20, 31] . In addition, to enable a directed immobilisation of the di¡erent proteins for binding studies, a codon for a unique cysteine residue was engineered into the C-termini of the di¡erent proteins. This strategy allowed for puri¢cation of the fusion proteins by HSA-a¤nity chromatography without employing their IgG binding activities (Figs. 1 and 2B) . Thus, any contamination of IgG which could have resulted from the use of IgG-a¤nity chromatography was avoided. The yields of the di¡erent fusion Fig. 2 . A: An alignment of the amino acid sequences of the ¢ve naturally occurring SPA domains and the synthetic analogue, Z [10] . The entire sequence for domain B is written out and a dash (-) means that the amino acid residue is identical to the residue in B. The three K-helices [43] are boxed. The domains B, C, A and Z consists of 58 amino acid residues each, domain E of 56 residues and domain D of 61 residues. The numbering follows Nilsson and coworkers [10] . B: The entire amino acid sequence of the fusion protein between the albumin binding domain of streptococcal protein G and domain B of SPA. Note the C-terminal extension containing a cysteine residue. All sequences are given in one letter code.
proteins after HSA-a¤nity chromatography were in the range of 6^30 mg l 3I culture. Analysis by SDS-PAGE showed that puri¢ed proteins were of full length and that approximately half of the material formed disul¢de bridged dimers under non-reducing conditions (data not shown).
Binding of HSA to the fusion proteins
To allow for binding experiments using real-time biosensor analysis, the six di¡erent fusion proteins containing individual SPA-derived domains were immobilised onto separate sensor chip surfaces through their C-terminal cysteine residues using thiol chemistry. All proteins could be e¤ciently immobilised to desired levels, indicating free accessibility of the cysteine residue. To address the integrity of the N-terminally located ABD moiety, the binding to HSA for each fusion proteins was studied at di¡erent HSA concentrations. All fusion proteins were demonstrated to bind to HSA with similar characteristics (data not shown). These two facts indicate that both regions of the fusion protein £anking the SPA domains are functional, suggesting that the central SPA-derived domain is intact.
Relative binding of SPA domains to Fc, polyclonal F(abP) P and scFv
To obtain a ranking of the relative binding strengths of the individual SPA-derived domains to a recombinant human IgG1 Fc fragment (Fc1*), polyclonal F(abP) P and scFv immunoglobulin fragments, the immobilised fusion proteins were subjected to single injections of the respective analytes at a high concentration and the responses recorded. To be able to compare the data, the responses were normalised with respect to the capability of the di¡erent immobilised ligands to bind HSA, injected at a single concentration, 1200 nM (`internal standard'). Thus, any di¡erences regarding variations in the proportions of functionally immobilised ligands were compensated for. All SPA domains including domain Z showed comparable binding to the Fc1* fragment, con¢rming a correct fold of the SPA-derived moieties of the fusion proteins (Fig. 3A) . To ensure that the observed binding was speci¢c, the binding to recombinant human Fc3 was analysed. As expected, none of the domains showed binding to the Fc3 fragment (data not shown).
Interestingly, injections of the human polyclonal F(abP) P analyte over the di¡erent immobilised ligands showed that all ¢ve native SPA domains are capable of binding also to Fab (Fig. 3B) . In contrast, the Fc1* binding domain Z, containing a single glycine to alanine substitution compared to domain B, showed dramatically lower F(abP) P binding (Fig. 3B ). An overlay plot of obtained sensorgrams underlines the di¡erence in binding to the polyclonal F(abP) P analyte for the closely related B and Z domains (Fig. 4A) . This analysis suggested that of the ¢ve native SPA domains, B and C bound most strongly to the F(abP) P analyte. Since the actual concentration of SPA binding F(abP) P fragments in the polyclonal preparation is unknown, the a¤nity constants for the interactions could not be determined.
Moreover, binding experiments were performed in which the polyclonal F(abP) P preparation was re- placed with a recombinant monoclonal scFv protein containing a V r sequence belonging to the human V r 3 family. Previous studies have shown that certain Fv fragments containing this subclass of V r sequences bind SPA and that C r 1 or C v domains do not contribute to the binding [32^34]. Analysis of the binding to the di¡erent domains using injections of a single concentration of this scFv immunoglobulin fragment showed that all ¢ve native SPA domains, but not domain Z, signi¢cantly bound the analyte. In addition, a similar ranking of the domains in terms of binding strength was observed using either scFv or F(abP) P , suggesting that this scFv fragment was functionally equivalent to F(abP) P for this comparative study. To further characterise the interactions, serial dilutions of the scFv fragment were passed over the di¡erent immobilised SPA domain fusion proteins and the responses monitored. From the data, both the on-and o¡-rates of the interactions were determined which allowed for a calculation of the respective apparent a¤nity constants, The results presented in Table 2 indicate that domains E, B, A and C bind the scFv fragment with somewhat higher a¤nities than domain D. These results correlate with the results using a single analyte concentration (Fig.  3C ). For domains E, A, B and C the apparent a¤n- ity constants are in the same order of magnitude as for the binding between human Fc1 fragments and a monovalent SPA domain [35] .
Discussion
In order to facilitate their puri¢cation and obtain directed immobilisation for binding studies, the individual protein A domains were produced as fusion proteins to a small N-terminal serum ABD derived from streptococcal protein G and a C-terminal GlySer-Cys-Gly-Ser extension, respectively (Fig. 2) . In addition, the ABD provided an internal reference for each fusion protein, certifying an intact N-terminal end of the fused SPA domain. The unique cysteine residue in the C-terminal extension of each fusion protein was used for directed disul¢de-linked immobilisation of the fusion proteins to activated sensor chip surfaces and thus served as a functional control since any truncated proteins devoid of the cysteine residue would not be immobilised. A control protein lacking cysteine residues could not be immobilised using the same immobilisation chemistry (data not shown). In addition, the experimental strategy provided identical orientation for all ligand molecules in contrast to most experiments reported earlier where antibodies or SPA fragments have been immobilised to microtitre wells or through amine coupling to various surfaces. For the expression of the fusion proteins, di¡erent cultivation conditions were tested. The factor most important for the yield was cultivation temperature, where 30³C gave higher yields than 37³C. IPTG concentration, time after induction and even which SPA domain the construction comprised were of less importance for the yield of fusion protein.
The scFv used as an alternative Fab reagent contains a V r heavy chain domain belonging to the human V r 3 family, DP-53 [23] , shown to bind to SPA [32^34] . When comparing the sequence of the V r 3 used in this study with the sequence of other known SPA-binding V r 3 sequences it is apparent that most amino acid residues reported to be important for good SPA binding is present in the DP-53 V r 3 [36^39]. The relevance of using this scFv was demonstrated by the similarity of binding between the scFv and human polyclonal F(abP) P (Fig. 3 ).
An important advantage obtained by using a recombinant scFv antibody as Fab fragment rather than a preparation puri¢ed from IgG is that there is no risk for contamination by intact IgG, containing Fc fragments with high a¤nity for SPA.
The most important conclusion from the experiments is that it was demonstrated for the ¢rst time that all ¢ve native protein A domains show comparable Fab binding. However, the binding analysis of separate monovalent protein A fragments to F(abP) P and to the scFv gave the unexpected result that domain B clearly binds Fab whereas the very similar domain Z shows only little or no binding activity. Although the observed weak binding for domain Z to Fab is in accordance with earlier results [40] , a stronger Fab binding of domain B is observed in this study as compared to precious ¢ndings [8, 40] . However, data such as shown in Fig. 4B strongly suggest that we observe a true biospeci¢c interaction.
The di¡erence in binding to Fab between B and Z is intriguing. The Z domain carries a glycine to alanine mutation (position 29) in the second of the three K-helices constituting the domain (Fig. 2A) . This change does not appear to interfere much with the binding to Fc, as demonstrated earlier [10] and in this work (Fig. 3A) . The alanine in domain Z does not point towards a possible ligand but instead towards helix 3 [10, 29] , suggesting the possibility that this helix might be involved in the binding to Fab, consistent with the hypothesis that the Fc-and Fabbinding sites are encoded by separate parts of protein A [41] or even by separate sites on an individual Ig-binding domain [9] . When comparing the structures of domains B and Z in solution by NMR [42] , there is a marked di¡erence in the orientation of helix 1 relative to the antiparallel helices 2 and 3. It is possible that this di¡erence in£uences the binding surface to Fab and thus generates the di¡erence in a¤nity.
It is noteworthy that our data for the Fab binding are based on only one of many possible SPA binding V r 3 domains and there might be di¡erences in speci¢city for di¡erent V r 3 sequences. Thus, there exists a possibility that the small di¡erences in binding observed between polyclonal F(abP) P and scFv (Fig.  3B,C) could be due to di¡erent speci¢cities of the SPA domains for di¡erent V r 3 motifs. However, the overall similarity in binding pattern between the domains obtained with human polyclonal F(abP) P suggests that the conclusions are generally valid. The di¡erences in Fab binding between B and Z are emphasised by examining the ratios of bound F(abP) P and scFv to the levels of functionally immobilised fusion proteins (Fig. 3) . While it is evident that domain B and the other native SPA domains show similar ratios for Fc and Fab, respectively, domain Z binds very little Fab compared to Fc.
Previously, domains E and/or D have been suggested to be responsible for the main Fab binding of protein A [8, 9, 42] . Our data does not support this hypothesis as domains A, B, and C in our experiments all bind Fab with similar strength as domains E and D. In conclusion, this work has demonstrated that all ¢ve native SPA domains E, D, A, B and C show a¤nity for both Fab and Fc. In contrast, the closely related domain Z shows signi¢cant binding only to Fc.
